



Health  
Canada

Santé  
Canada

# Natural and Non-Prescription Health Products Directorate

Drug Submission Performance  
Quarterly Report  
July – September  
2018



Health Canada is responsible for helping Canadians maintain and improve their health. It ensures that high quality health services are accessible, and works to reduce health risks.

Également disponible en français sous le titre :  
Direction des produits de santé naturels et sans ordonnance – Rapport trimestriel du rendement des  
présentations de drogue – juillet – septembre 2018

To obtain additional information, please contact:

Health Canada  
Address Locator 0900C2  
Ottawa, On K1A 0K9  
Tel.: 613-957-2991  
Toll free: 1-866-225-0709  
Fax: 613-941-5366  
TTY: 1-800-465-7735  
E-mail: [hc.publications-publications.sc@canada.ca](mailto:hc.publications-publications.sc@canada.ca)

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2018

Publication date: November 2018

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat H167-3E-PDF  
ISSN 2561-5556  
Pub 180532

## Table of Contents

<b>OVERVIEW .....</b>	<b>9</b>
<b>ACRONYMS .....</b>	<b>12</b>
Submission Types .....	12
Documents .....	12
<b>FEE CATEGORIES .....</b>	<b>13</b>
<b>PART 1: NON-PRESCRIPTION DRUGS .....</b>	<b>14</b>
<b>NON PRESCRIPTION DRUGS FILED PURSUANT TO DIVISION 1 .....</b>	<b>14</b>
<b>DINA: DRUG IDENTIFICATION NUMBER APPLICATIONS .....</b>	<b>15</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>15</b>
DINA: Received by Fee Category .....	15
<b>WORKLOAD .....</b>	<b>16</b>
DINA: Review Workload Showing Percentage in Backlog .....	16
DINA: Review Workload by Fee Category .....	16
DINA: Screening Workload Showing Percentage in Backlog .....	17
DINA: Screening Workload by Fee Category .....	17
DINA: Administrative-Screening Workload Showing Percentage in Backlog .....	18
DINA: Administrative-Screening Workload by Fee Category .....	18
<b>DECISION DOCUMENTS .....</b>	<b>19</b>
DINA: Decision Documents by Fee Category .....	19
<b>PERFORMANCE .....</b>	<b>20</b>
DINA: Review Cycle Completions Showing Percentage within Target .....	20
DINA: Screening Cycle Completions Showing Percentage within Target .....	20
DINA: Administrative-Screening Cycle Completions Showing Percentage within Target .....	21

<b>DINF: CATEGORY FOUR DIN APPLICATIONS .....</b>	<b>22</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>22</b>
DINF: Received by Fee Category.....	22
<b>WORKLOAD .....</b>	<b>23</b>
DINF: Screening Workload Showing Percentage in Backlog .....	23
DINF: Screening Workload by Fee Category .....	23
<b>DECISION DOCUMENTS.....</b>	<b>24</b>
DINF: Decision Documents by Fee Category .....	24
<b>PERFORMANCE.....</b>	<b>25</b>
DINF: Screening Cycle Completions .....	25
DINF: Admin-Screening Cycle Completions .....	25
<b>PDC: POST AUTHORIZATION DIVISION 1 CHANGES.....</b>	<b>26</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>26</b>
PDC: Received by Fee Category .....	26
<b>WORKLOAD .....</b>	<b>27</b>
PDC: Screening Workload Showing Percentage in Backlog .....	27
PDC: Screening Workload by Fee Category .....	27
<b>DECISION DOCUMENTS.....</b>	<b>28</b>
PDC: Decision Documents by Fee Category .....	28
<b>PERFORMANCE.....</b>	<b>28</b>
PDC: Screening Cycle Completions .....	28
<b>NON-PRESCRIPTION DRUGS FILED PURSUANT TO DIVISION 8.....</b>	<b>29</b>
<b>NDS: NEW DRUG SUBMISSIONS.....</b>	<b>30</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>30</b>
NDS: Received by Fee Category .....	30
<b>WORKLOAD .....</b>	<b>31</b>
NDS: Review Workload Showing Percentage in Backlog .....	31
NDS: Review Workload by Fee Category .....	31

NDS: Screening Workload Showing Percentage in Backlog .....	32
NDS: Screening Workload by Fee Category .....	32
<b>DECISION DOCUMENTS .....</b>	<b>33</b>
NDS: Decision Documents by Fee Category .....	33
<b>PERFORMANCE .....</b>	<b>34</b>
NDS: Review Cycle Completions Showing Percentage within Target .....	34
NDS: Screening Cycle Completions Showing Percentage within Target .....	34
<b>SNDS: SUPPLEMENTAL NEW DRUG SUBMISSIONS.....</b>	<b>35</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>35</b>
SNDS: Received by Fee Category .....	35
<b>WORKLOAD .....</b>	<b>36</b>
SNDS: Review Workload Showing Percentage in Backlog .....	36
SNDS: Review Workload by Fee Category .....	36
SNDS: Screening Workload Showing Percentage in Backlog .....	37
SNDS: Screening Workload by Fee Category .....	37
<b>DECISION DOCUMENTS .....</b>	<b>38</b>
SNDS: Decision Documents by Fee Category .....	38
<b>PERFORMANCE .....</b>	<b>39</b>
SNDS: Review Cycle Completions Showing Percentage within Target .....	39
SNDS: Screening Cycle Completions Showing Percentage within Target .....	39
<b>NC: NOTIFIABLE CHANGES .....</b>	<b>40</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>40</b>
NC: Received by Fee Category .....	40
<b>WORKLOAD .....</b>	<b>41</b>
NC: Review Workload Showing Percentage in Backlog.....	41
NC: Review Workload by Fee Category .....	41
NC: Screening Workload Showing Percentage in Backlog.....	42
NC: Screening Workload by Fee Category .....	42
<b>DECISION DOCUMENTS .....</b>	<b>43</b>
NC: Decision Documents by Fee Category .....	43

<b>PERFORMANCE.....</b>	<b>44</b>
NC: Review Cycle Completions Showing Percentage within Target.....	44
NC: Screening Cycle Completions Showing Percentage within Target .....	44
<b>MPDIN: PRE-DIN MEETING .....</b>	<b>45</b>
MPDIN – Pre-DIN Meeting Received by Fee Category .....	45
<b>MPNDS: PRE-NDS MEETING.....</b>	<b>45</b>
MPNDS – Pre-NDS Meeting Received by Fee Category.....	45
<b>MPSNDS: PRE-SNDS MEETING .....</b>	<b>45</b>
MPSNDS – Pre-SNDS Meeting Received by Fee Category .....	45
<b>PART 2: DISINFECTANT DRUGS .....</b>	<b>46</b>
<b>DISINFECTANT DRUGS FILED PURSUANT TO DIVISION 1 .....</b>	<b>46</b>
<b>DIND: DIN APPLICATION – DISINFECTANT DRUGS.....</b>	<b>47</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>47</b>
DIND: Received by Fee Category .....	47
<b>WORKLOAD .....</b>	<b>48</b>
DIND: Review Workload Showing Percentage in Backlog .....	48
DIND: Screening Workload Showing Percentage in Backlog.....	48
DIND: Administrative-Screening Workload Showing Percentage in Backlog .....	49
<b>PERFORMANCE.....</b>	<b>50</b>
DIND: Review Performance Showing Percentage within Target.....	50
DIND: Screening Performance Showing Percentage within Target .....	50
DIND: Administrative-Screening Performance Showing Percentage within Target.....	51
<b>DECISION DOCUMENTS.....</b>	<b>52</b>
DIND: Decisions Documents by Fee Category .....	52
<b>PDC: POST AUTHORIZATION DIVISION 1 CHANGES.....</b>	<b>53</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>53</b>

PDC: Received by Fee Category .....	53
<b>WORKLOAD .....</b>	<b>54</b>
PDC: Screening Workload Showing Percentage in Backlog.....	54
<b>PERFORMANCE .....</b>	<b>54</b>
PDC: Screening Performance Showing Percentage within Target.....	54
<b>DECISION DOCUMENTS .....</b>	<b>55</b>
PDC: Decision Documents by Fee Category.....	55
<b>DISINFECTANT DRUGS FILED PURSUANT TO DIVISION 8.....</b>	<b>56</b>
<b>NDS-D: NEW DRUG SUBMISSIONS-DISINFECTANT DRUGS .....</b>	<b>57</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>57</b>
NDS-D: Received by Fee Category.....	57
<b>WORKLOAD .....</b>	<b>57</b>
NDS-D: Review Workload/Backlog at End of Quarter.....	57
NDS-D: Screening Workload/Backlog at End of Quarter .....	57
NDS-D: Administrative-Screening Workload/Backlog at End of Quarter.....	57
<b>PERFORMANCE .....</b>	<b>58</b>
NDS-D: Review Performance .....	58
NDS-D: Screening Performance.....	58
NDS-D: Administrative-Screening Performance .....	58
<b>DECISION DOCUMENTS .....</b>	<b>58</b>
NDS-D: Decision Documents by Fee Category .....	58
<b>NC: NOTIFIABLE CHANGES .....</b>	<b>59</b>
<b>SUBMISSIONS RECEIVED.....</b>	<b>59</b>
NC – Disinfectant Drugs: Received by Fee Category .....	59
<b>WORKLOAD .....</b>	<b>59</b>
NC – Disinfectant Drugs: Review Workload/Backlog at End of Quarter .....	59
NC – Disinfectant Drugs: Screening Workload/Backlog at End of Quarter.....	59
<b>PERFORMANCE .....</b>	<b>60</b>

NC – Disinfectant Drugs: Review Performance .....	60
NC – Disinfectant Drugs: Screening Performance .....	60
<b>DECISION DOCUMENTS.....</b>	<b>60</b>
NC – Disinfectant Drugs: Decision Documents .....	60
<b>MPNDS: PRE-NDS MEETING.....</b>	<b>61</b>
MPNDS – Disinfectant Drugs: Received by Fee Category .....	61
<b>MPSNDS: PRE-SNDS MEETING .....</b>	<b>61</b>
MPSNDS – Disinfectant Drugs: Received by Fee Category .....	61



# OVERVIEW

The NNHPD Quarterly Drug Submission Performance Report reflects Non-Prescription and Disinfectant Drug submission review activity over five consecutive quarters from July – September 2017 to July – September 2018. Statistics are provided by Submission Type and show the number received, the number in workload and the number of licensing decisions issued over that period.

Some of the highlights of the July – September 2018 report are:

## **Non-Prescription (Over the Counter (OTC) drugs:**

- There was a decrease (25%) in the number of DINA submissions received: from 28 in April-June 2018 to 21 during this quarter (July-September 2018).
- The number of PDC submissions received decreased (39%): from 72 in April-June 2018 to 44 this quarter (July-September 2018).
- There was a slight decrease (6%) in the number of DINF submissions received: from 35 in April-June 2018 to 33 during this quarter (July-September 2018).
- There was a significant (233%) increase in the number of SNDS received this quarter as compared to the previous 4 quarters (i.e., 3-3-3-3-7), while the number of NDS received remained the same as the previous quarter (i.e., with 0 received).
- The number of NCs received during this past quarter has stabilized to previous levels as compared to the previous 4 quarters (i.e., 3-5-5-13-6), however the number received this quarter represents a 216% reduction as compared to the previous quarter (i.e., April-June 2018).
- Overall, total non-prescription drug submissions received decreased by 25% during this past quarter (114) compared to last quarter (153).

## **Disinfectant Drugs:**

- The number of DIND submissions received this quarter has remained stable as compared to the previous quarter (i.e., 34 in July-September 2018 compared to 35 in April-June 2018).
- There was a significant (42%) decrease in the number of PDC submissions received in this quarter (i.e., 7 in July-September 2018 compared to 12 in April-June 2018).
- Overall, total disinfectant drug submissions received decreased by 13% during this past quarter (42) compared to last quarter (48).

## General Information

There are several steps involved in the drug submission review<sup>1</sup> and approval process:

- administrative processing,
- regulatory and scientific screening and
- in-depth scientific review.

When deficiencies or non-compliance issues are found, a company may submit responses before a final decision can be reached and thus multiple review cycles may be required.

A submission's approval time can vary depending on the number and type of review cycles needed.

**Submissions Received** are counts of submissions received during the year using the filing date (CR date) which is the date the submission is considered administratively complete by Health Canada.

**Workload** is the number of submissions “under active review” on the last day of the quarter. **“Backlog”** is the proportion of the workload that is over target. Often the term workload is used to mean the amount of work received over a period of time and is a common source of confusion.

For new drugs, **approvals** are Notice of Compliances (NOC) Issued or Issuable which are reported in the Decisions’ section. An NOC issuable is when a submission’s NOC is placed “on hold” awaiting authorization to market, due to changes from Prescription to Non-Prescription or due to Patented Medicines (NOC) Regulations.

---

<sup>1</sup> For further clarification refer to the [Guidance for Industry: Management of Drug Submissions](#).

A **review cycle completion** is counted upon the conclusion of a scientific review that then results in a decision of approval or non-approval. The time taken is compared to a set [performance standard](#)<sup>2</sup> which is based on the type of submission, class and cycle (status). Health Canada has set a goal of 90% of review cycle completions to be rendered within performance standards.

Any questions or comments on this report should be forwarded to:

Office of Submissions and Intellectual Property  
Finance Building, A.L. # 0202A1  
101 Tunney's Pasture Driveway, Tunney's Pasture  
Ottawa, Ontario, K1A 0K9

Tel: (613) 941-7281 Fax: (613) 941-0825

Email: [hc.osip-bppi.sc@canada.ca](mailto:hc.osip-bppi.sc@canada.ca)

---

<sup>2</sup> Performance continues to be measured against performance standards for Submission Type/Submission Class/ Status combinations as set out in Appendix 3 of the [Guidance for Industry: Management of Drug Submissions](#). This is not to be confused with the 'UF Review 1 (iteration 1)' performance standards that are employed to measure performance to meet the *User Fees Act* reporting Requirements in the 'Health Canada Departmental Performance Report (DPR)'.

# ACRONYMS

## Submission Types

ANDS	-	Abbreviated New Drug Submission
DINA	-	Application for a Drug Identification Number
DIND	-	Application for a Drug Identification Number – Disinfectant Product
DINF	-	Application for a Drug Identification Number - Category IV Product – (Labelling Standard)
MPNDS		Pre-NDS Meeting
NC	-	Notifiable Change – New Drug
NDS	-	New Drug Submission
NDS-D		New Drug Submission - Disinfectants
PDC	-	Post-DIN Changes
SNDS	-	Supplemental New Drug Submission

## Documents

NOC	-	Notice of Compliance
NOC-c	-	Notice of Compliance with Conditions
Issuable NOC (Patent)	-	NOC on Hold due to Patented Medicines (NOC) Regulations
Issuable NOC (Rx to OTC)	-	NOC on Hold due to changes (Prescription to Non-Prescription)
NON	-	Notice of Non-Compliance
NOD	-	Notice of Deficiency
NON Withdrawal	-	Notice of Non-Compliance Withdrawal Letter
NOD Withdrawal	-	Notice of Deficiency Withdrawal Letter

## Fee Categories

Fee Category	Fee Category Description
<b>New Active Substance (NAS)</b>	Submission in support of a drug, excluding a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada, and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph. For biologics, this submission class does not include an NDS in support of a subsequent entry biologic or an SNDS in support of changes to the manufacturing process of biologics.
<b>Clinical or Non-Clinical Data and Chemistry and Manufacturing data</b>	Submissions based on clinical or non-clinical data <b>and</b> chemistry and manufacturing data for a drug that does not include a NAS.
<b>Clinical or Non-Clinical Data Only</b>	Submissions based only on clinical or non-clinical data for a drug that does not include a NAS.
<b>Comparative Studies</b>	Submissions based on comparative studies with or without chemistry and manufacturing data for a drug that does not include a NAS. It excludes superiority and non-inferiority studies since they are clinical studies. It also excludes pharmaceutical equivalence studies since they are captured by the chemistry and manufacturing fee.
<b>Chemistry and Manufacturing Data Only</b>	Submissions based only on chemistry and manufacturing data for a drug that does not include a NAS.
<b>Published Data Only</b>	Submissions based only on published clinical or non-clinical data for a drug that does not include a NAS.
<b>Switch from Prescription to Nonprescription Status</b>	Submissions based only on data that support the modification or removal of a medicinal ingredient on the <a href="#">Prescription Drug List</a> . This fee is limited to switches from prescription to nonprescription status when an identical claim is made for an existing drug.
<b>Labelling Only<sup>3</sup></b>	Submissions of labelling material that do not include supporting clinical or non-clinical data or chemistry and manufacturing data.
<b>Administrative Submission<sup>4</sup></b>	Submissions in support of a manufacturer or product name change.
<b>Disinfectants<sup>5</sup></b>	Submissions and applications that include data in support of a disinfectant.
<b>Drug Identification Number (DIN) - Labelling Standards</b>	Applications attesting to compliance with a labelling standard or Category IV Monograph (DINF) for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data.

For further information, please refer to the [Guidance Document - Fees for the Review of Drug Submissions and Applications](#)

<sup>3</sup> For more information, please consult the [Guidance Document: Question and Answers about Plain Language Labelling](#)

<sup>4</sup> For additional information, please consult the ["Changes in Manufacturer and/or Product Name Policy" \(2015\)](#)

<sup>5</sup> The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported on in a separate NNHPD Drug Submission Performance Report.

# **PART 1: NON-PRESCRIPTION DRUGS**

## **Over the counter (OTC) Drugs**


**NON PRESCRIPTION DRUGS FILED PURSUANT TO DIVISION 1**

**in Part C of the *Food and Drug Regulations***

## DINA: DRUG IDENTIFICATION NUMBER APPLICATIONS


### SUBMISSIONS RECEIVED

#### DINA: Received by Fee Category



## WORKLOAD

### DINA: Review Workload Showing Percentage in Backlog




### DINA: Review Workload by Fee Category

NNHPD DINA REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Chemistry and Manufacturing</b>	<b>3</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Clinical or Non-Clinical Data</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>1</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Clinical or Non-Clinical Data and Chemistry - Manufacturing</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>1</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Labelling Only</b>	<b>20</b>	<b>19</b>	<b>19</b>	<b>30</b>	<b>31</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Published Data</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Total</b>	<b>27</b>	<b>22</b>	<b>21</b>	<b>32</b>	<b>35</b>
<b>Non Backlog</b>	<b>27</b>	<b>22</b>	<b>21</b>	<b>32</b>	<b>35</b>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>



## WORKLOAD

### DINA: Screening Workload Showing Percentage in Backlog




### DINA: Screening Workload by Fee Category

NNHPD DINA SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Chemistry and Manufacturing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Backlog	0	0	0	0	0
<b>Clinical or Non-Clinical</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Backlog	0	0	0	0	0
<b>Clinical or Non-Clinical Data and Chemistry - Manufacturing</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Backlog	0	0	0	0	0
<b>Labelling Only</b>	<b>4</b>	<b>5</b>	<b>21</b>	<b>13</b>	<b>8</b>
Backlog	0	0	0	0	0
<b>Labelling Standard</b>	<b>3</b>	<b>4</b>	<b>10</b>	<b>12</b>	<b>5</b>
Backlog	0	0	0	0	0
<b>Published Data</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Backlog	0	0	0	0	0
<b>Total</b>	<b>8</b>	<b>9</b>	<b>31</b>	<b>25</b>	<b>13</b>
<b>Non Backlog</b>	<b>8</b>	<b>9</b>	<b>31</b>	<b>25</b>	<b>13</b>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## WORKLOAD

### DINA: Administrative-Screening Workload Showing Percentage in Backlog



### DINA: Administrative-Screening Workload by Fee Category

NNHPD DINA ADMIN SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Administrative</b>	<b>11</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>2</b>
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>11</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>2</b>
<b>Non Backlog</b>	11	0	2	0	2
<b>BACKLOG</b>	0	0	0	0	0
<b>% in Backlog</b>	0%	0%	0%	0%	0%


## DECISION DOCUMENTS

## DINA: Decision Documents by Fee Category


User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
ADMINISTRATIVE	CANCELLATION LETTER	3	15	18	5	1
	NOTIFICATION FORM DIN SUB	11	0	0	0	0
	REJECTION LETTER (SCR)	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	1	0	0	0	0
	NO OBJECTION LETTER	0	0	0	0	0
CHEMISTRY AND MANUFACTURING	NOTICE OF DEFICIENCY	0	0	0	0	0
	NOTICE OF NON-COMPLIANCE	1	3	0	0	0
	NOTIFICATION FORM DIN SUB	0	0	0	0	0
	NO OBJECTION LETTER	0	0	0	0	1
	CANCELLATION LETTER	0	2	2	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
	WITHDRAWAL NO RESP TO NON	0	0	0	0	0
CLINICAL OR NON-CLINICAL DATA	NOTIFICATION FORM DIN SUB	0	1	0	0	0
	NOTICE OF NON-COMPLIANCE	0	1	0	0	0
	NO OBJECTION LETTER	0	0	1	0	0
	SCREENING DEFICIENCY NOTICE	0	0	1	0	0
	CANCELLATION LETTER	0	0	0	1	0
CLINICAL OR NON CLINICAL DATA AND CHEMISTRY - MANUFACTURING	SCREENING DEFICIENCY NOTICE	1	0	0	0	0
	NOTICE OF NON-COMPLIANCE	0	0	0	1	0
COMPARATIVE STUDIES WITH OR WITHOUT CHEMISTRY - MANUFACTURING	NOTIFICATION FORM DIN SUB	0	0	0	0	0
LABELLING ONLY	CANCELLATION LETTER	5	0	8	4	0
	NO OBJECTION LETTER	1	0	0	0	1
	NOTICE OF NON-COMPLIANCE	0	0	0	3	2
	NOTICE OF DEFICIENCY	0	1	0	1	1
	NOTIFICATION FORM DIN SUB	8	9	11	7	7
	REJECTION LETTER (SCR)	0	0	1	0	2
	SCREENING DEFICIENCY NOTICE	5	7	5	5	6
	WITHDRAWAL NO RESP TO NOD	0	0	0	0	1
	WITHDRAWAL NO RESP TO NON	0	0	0	1	0
LABELLING STANDARD	CANCELLATION LETTER	0	0	0	1	3
	NO OBJECTION LETTER	0	0	0	0	0
	NOTIFICATION FORM DIN SUB	5	6	10	4	13
	REJECTION LETTER (SCR)	0	0	0	0	1
	SCREENING DEFICIENCY NOTICE	10	2	1	9	6
PUBLISHED DATA	SCREENING DEFICIENCY NOTICE	0	0	1	0	0
	NOTICE OF NON-COMPLIANCE	0	0	0	0	0
	CANCELLATION LETTER	0	0	0	1	0
	NON WITHDRAWAL LETTER	0	0	0	0	0
	NOTIFICATION FORM DIN SUB	0	0	1	0	0

## PERFORMANCE

### DINA: Review Cycle Completions Showing Percentage within Target





### DINA: Screening Cycle Completions Showing Percentage within Target



## PERFORMANCE


## DINA: Administrative-Screening Cycle Completions Showing Percentage within Target



**DINF: CATEGORY FOUR DIN APPLICATIONS****SUBMISSIONS RECEIVED****DINF: Received by Fee Category**

## WORKLOAD

### DINF: Screening Workload Showing Percentage in Backlog



### DINF: Screening Workload by Fee Category

NNHPD DINF SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Labelling Standard</b>	<b>19</b>	<b>38</b>	<b>45</b>	<b>25</b>	<b>20</b>
<i>Backlog</i>	0	0	0	0	0
<b>Administrative</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>19</b>	<b>38</b>	<b>45</b>	<b>25</b>	<b>20</b>
<b>Non Backlog</b>	19	38	45	25	20
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## DECISION DOCUMENTS


## DINF: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
LABELLING STANDARD	CANCELLATION LETTER	0	1	1	5	2
	NO OBJECTION LETTER	1	0	0	0	2
	NEW DRUG LETTER SCREEN	1	0	0	0	0
	NOTIFICATION FORM DIN SUB	36	15	29	53	39
	REJECTION LETTER (SCR)	1	1	0	6	1
	SCREENING DEFICIENCY NOTICE	12	25	31	43	18
ADMINISTRATIVE	REJECTION LETTER (SCR)	0	0	0	0	0
	NOTIFICATION FORM DIN SUB	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
	CANCELLATION LETTER	0	1	1	0	0





## PERFORMANCE

### DINF: Screening Cycle Completions




### DINF: Admin-Screening Cycle Completions



**PDC: POST AUTHORIZATION DIVISION 1 CHANGES****SUBMISSIONS RECEIVED****PDC: Received by Fee Category**

## WORKLOAD

### PDC: Screening Workload Showing Percentage in Backlog



### PDC: Screening Workload by Fee Category

NNHPD PDC SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Regular</b>	<b>24</b>	<b>1</b>	<b>11</b>	<b>18</b>	<b>8</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>1</i>	<i>0</i>
<b>Total</b>	<b>24</b>	<b>1</b>	<b>11</b>	<b>18</b>	<b>8</b>
<b>Non Backlog</b>	<b>24</b>	<b>1</b>	<b>11</b>	<b>17</b>	<b>8</b>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>6%</b>	<b>0%</b>


## DECISION DOCUMENTS

### PDC: Decision Documents by Fee Category


User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
REGULAR	CANCELLATION LETTER	1	1	0	3	6
	NO OBJECTION LETTER	114	60	24	57	40
	NOT SATISFACTORY NOTICE	2	4	3	7	6
	SCREENING DEFICIENCY NOTICE	0	0	0	0	1

## PERFORMANCE

### PDC: Screening Cycle Completions




**NON-PRESCRIPTION DRUGS FILED PURSUANT TO DIVISION 8  
in Part C of the *Food and Drug Regulations***

**NDS: NEW DRUG SUBMISSIONS****SUBMISSIONS RECEIVED****NDS: Received by Fee Category**

## WORKLOAD

### NDS: Review Workload Showing Percentage in Backlog




### NDS: Review Workload by Fee Category

NNHPD NDS REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Clinical or Non-Clinical Data and Chemistry - Manufacturing	0	0	1	1	2
Backlog	0	0	0	0	0
Comparative Studies with or without Chemistry - Manufacturing	0	0	0	0	1
Backlog	0	0	0	0	0
Labelling Only	1	0	1	0	0
Backlog	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>3</b>
Non Backlog	1	0	2	1	3
BACKLOG	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%

## WORKLOAD

### NDS: Screening Workload Showing Percentage in Backlog



### NDS: Screening Workload by Fee Category

NNHPD NDS SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Prescription to Non-Prescription Switch	0	0	0	0	0
Backlog	0	0	0	0	0
Published Data	0	0	0	0	0
Backlog	0	0	0	0	0
Clinical or Non-Clinical Data and Chemistry - Manufacturing	0	0	1	1	0
Backlog	0	0	0	0	0
Labelling Only	1	1	1	1	1
Backlog	1	1	1	1	1
Comparative Studies with or without Chemistry - Manufacturing	0	1	1	1	0
Backlog	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>1</b>
Non Backlog	0	1	2	2	0
BACKLOG	1	1	1	1	1
% in Backlog	100%	50%	33%	33%	100%



## DECISION DOCUMENTS


## NDS: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
ADMINISTRATIVE	CANCELLATION LETTER	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CLINICAL OR NON CLINICAL DATA AND CHEMISTRY - MANUFACTURING	SCREENING DEFICIENCY NOTICE	0	1	0	1	0
	NOD WITHDRAWAL LETTER	0	0	0	0	0
	NOTICE OF COMPLIANCE*	0	0	0	0	0
	NOC ON HOLD (SWITCH)*	0	0	0	0	0
COMPARATIVE STUDIES WITH OR WITHOUT CHEMISTRY - MANUFACTURING	NOC ON HOLD (SWITCH)*	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	1	0
LABELLING ONLY	NOTICE OF COMPLIANCE*	4	0	0	1	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
	CANCELLATION LETTER	0	1	0	0	0
PUBLISHED DATA ONLY	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
PRESCRIPTION TO NON-PRESCRIPTION SWITCH	NOC ON HOLD (SWITCH)*	0	0	0	0	0


\*Approvals are the NOCs Issued or Issuable at the conclusion of review (not NOCs issued at the end of a switch or patent hold).

## PERFORMANCE

### NDS: Review Cycle Completions Showing Percentage within Target




### NDS: Screening Cycle Completions Showing Percentage within Target



## SNDS: SUPPLEMENTAL NEW DRUG SUBMISSIONS


### SUBMISSIONS RECEIVED

#### SNDS: Received by Fee Category



## WORKLOAD

### SNDS: Review Workload Showing Percentage in Backlog




### SNDS: Review Workload by Fee Category

NNHPD SNDS REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Clinical or Non-Clinical Data	1	1	1	0	0
Backlog	0	0	0	0	0
Clinical or Non-Clinical Data and Chemistry - Manufacturing	0	0	0	0	0
Backlog	0	0	0	0	0
Labelling Only	1	1	2	1	5
Backlog	0	0	0	0	0
Published Data	0	0	0	0	0
Backlog	0	0	0	0	0
Prescription to Non-Prescription Switch	0	0	1	1	0
Backlog	0	0	0	0	0
Comparative Studies with or without Chemistry - Manufacturing	1	1	2	1	1
Backlog	0	0	0	0	0
Chemistry and Manufacturing	2	6	4	1	1
Backlog	0	1	0	0	0
<b>Total</b>	<b>5</b>	<b>9</b>	<b>10</b>	<b>4</b>	<b>7</b>
Non Backlog	5	8	10	4	7
BACKLOG	0	1	0	0	0
% in Backlog	0%	11%	0%	0%	0%

## WORKLOAD

### SNDS: Screening Workload Showing Percentage in Backlog



### SNDS: Screening Workload by Fee Category

NNHPD SNDS SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Chemistry and Manufacturing</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>2</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Clinical or Non-Clinical Data</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Comparative Studies with or without Chemistry - Manufacturing</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Labelling Only</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Published Data</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Total</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>3</b>
<b>Non Backlog</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>3</b>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## DECISION DOCUMENTS


## SNDS: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
CLINICAL OR NON-CLINICAL DATA	NOC ON HOLD (SWITCH)*	0	0	0	0	0
	NOTICE OF COMPLIANCE*	0	0	0	1	0
CLINICAL OR NON CLINICAL DATA AND CHEMISTRY - MANUFACTURING	NOTICE OF COMPLIANCE*	0	0	0	0	0
COMPARATIVE STUDIES WITH OR WITHOUT CHEMISTRY - MANUFACTURING	NOTICE OF COMPLIANCE*	0	0	0	0	1
	NOTICE OF NON-COMPLIANCE	0	0	0	1	0
	NOTICE OF DEFICIENCY	0	1	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
LABELLING ONLY	NOC ON HOLD (SWITCH)*	0	0	0	0	0
	NOTICE OF COMPLIANCE*	2	0	2	2	1
	SCREENING DEFICIENCY NOTICE	0	0	1	0	2
	CANCELLATION LETTER	0	0	0	0	0
	NOTICE OF DEFICIENCY	0	0	0	0	0
	NOTICE OF NON-COMPLIANCE	0	1	0	1	1
PRESRIPTION TO NON-PRESRIPTION SWITCH	NOC ON HOLD (SWITCH) *	0	0	0	0	1
PUBLISHED DATA ONLY	CANCELLATION LETTER	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
	NOTICE OF COMPLIANCE*	1	0	0	0	0
ADMINISTRATIVE	CANCELLATION LETTER	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CHEMISTRY AND MANUFACTURING	NOTICE OF NON-COMPLIANCE	0	0	0	1	0
	NOTICE OF COMPLIANCE*	1	0	2	3	0
	SCREENING DEFICIENCY NOTICE	3	0	1	0	0


\*Approvals are the NOCs Issued or Issuable at the conclusion of review (not NOCs issued at the end of a switch or patent hold).


## PERFORMANCE

### SNDS: Review Cycle Completions Showing Percentage within Target



### SNDS: Screening Cycle Completions Showing Percentage within Target




**NC: NOTIFIABLE CHANGES****SUBMISSIONS RECEIVED****NC: Received by Fee Category**



## WORKLOAD

### NC: Review Workload Showing Percentage in Backlog




### NC: Review Workload by Fee Category

NNHPD NC REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Safety 90</b>	<b>3</b>	<b>5</b>	<b>3</b>	<b>8</b>	<b>7</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Safety 120</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Total</b>	<b>3</b>	<b>5</b>	<b>3</b>	<b>8</b>	<b>7</b>
<b>Non Backlog</b>	<b>3</b>	<b>5</b>	<b>3</b>	<b>8</b>	<b>7</b>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## WORKLOAD

### NC: Screening Workload Showing Percentage in Backlog





### NC: Screening Workload by Fee Category

NNHPD NC SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>Safety 90</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Non Backlog</b>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>0</i>
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## DECISION DOCUMENTS

## NC: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
SAFETY 90	NO OBJECTION LETTER	7	3	5	3	8
	NC-HOLD (SWITCH)	0	0	0	0	0
	NOT SATISFACTORY NOTICE	0	0	0	0	0
	REJECTION LETTER (SCR)	0	0	0	1	0
	CANCELLATION LETTER	1	1	0	1	4
	SCREENING DEFICIENCY NOTICE	0	4	0	7	4
SAFETY 120	CANCELLATION LETTER	0	0	0	0	0

**PERFORMANCE****NC: Review Cycle Completions Showing Percentage within Target****NC: Screening Cycle Completions Showing Percentage within Target**

**MPDIN: PRE-DIN MEETING****MPDIN – Pre-DIN Meeting Received by Fee Category**

PRE - DIN MEETING (MPDIN)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
CLINICAL OR NON-CLINICAL DATA	0	0	0	0	1

**MPNDS: PRE-NDS MEETING****MPNDS – Pre-NDS Meeting Received by Fee Category**

PRE - NDS MEETING (MPNDS)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
CLINICAL OR NON-CLINICAL DATA AND CHEMISTRY - MANUFACTURING	0	0	0	0	2


**MPSNDS: PRE-SNDS MEETING****MPSNDS – Pre-SNDS Meeting Received by Fee Category**

PRE - NDS MEETING (MPSNDS)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
CLINICAL OR NON-CLINICAL DATA	0	0	0	1	0

## **PART 2: DISINFECTANT DRUGS**


**DISINFECTANT DRUGS FILED PURSUANT TO DIVISION 1**

**in Part C of the *Food and Drug Regulations***


**DIND: DIN APPLICATION – DISINFECTANT DRUGS****SUBMISSIONS RECEIVED****DIND: Received by Fee Category**

## WORKLOAD

### DIND: Review Workload Showing Percentage in Backlog




### DIND: Screening Workload Showing Percentage in Backlog






## WORKLOAD

### DIND: Administrative-Screening Workload Showing Percentage in Backlog




## PERFORMANCE

### DIND: Review Performance Showing Percentage within Target




### DIND: Screening Performance Showing Percentage within Target



## PERFORMANCE


### DIND: Administrative-Screening Performance Showing Percentage within Target



## DECISION DOCUMENTS


## DIND: Decisions Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
ADMINISTRATIVE	CANCELLATION LETTER	1	0	0	2	0
	NO OBJECTION LETTER	0	0	0	0	1
	DIN INCORR SUBTYPE-CLASS	0	0	0	0	0
	NOTIFICATION FORM DIN SUB	16	30	27	10	12
	REJECTION LETTER (SCR)	7	3	0	0	0
	SCREENING DEFICIENCY NOTICE	3	8	1	0	7
DISINFECTANTS	DIN INCORR SUBTYPE-CLASS	0	0	0	0	0
	NO OBJECTION LETTER	1	2	7	0	0
	CANCELLATION LETTER	1	2	0	0	1
	NEW DRUG LETTER SCREEN	0	0	0	0	0
	NOD WITHDRAWAL LETTER	0	0	0	0	0
	NON WITHDRAWAL LETTER	0	0	0	0	0
	NOTICE OF DEFICIENCY	0	0	0	0	0
	NOTICE OF NON-COMPLIANCE	0	1	0	0	0
	NOTIFICATION FORM DIN SUB	9	10	7	7	12
	SCREENING DEFICIENCY NOTICE	2	1	2	2	2
	REJECTION LETTER (SCR)	0	0	0	0	0
	WITHDRAWAL NO RESP TO NON	0	0	0	0	0
LABELLING STANDARD	NOTIFICATION FORM DIN SUB	3	3	6	5	5
	NO OBJECTION LETTER	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	1	2	5	1	3
	REJECTION LETTER (SCR)	3	0	0	3	1

**PDC: POST AUTHORIZATION DIVISION 1 CHANGES****SUBMISSIONS RECEIVED****PDC: Received by Fee Category**


## WORKLOAD

### PDC: Screening Workload Showing Percentage in Backlog



## PERFORMANCE

### PDC: Screening Performance Showing Percentage within Target



## DECISION DOCUMENTS

## PDC: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
ADMINISTRATIVE	CANCELLATION LETTER	0	0	1	0	0
REGULAR	CANCELLATION LETTER	0	0	0	0	0
	NO OBJECTION LETTER	17	21	15	15	4
	NOT SATISFACTORY NOTICE	17	9	0	1	5
	NOTIFICATION FORM DIN SUB	0	0	3	0	0
	REJECTION LETTER (SCR)	1	2	0	0	0

**DISINFECTANT DRUGS FILED PURSUANT TO DIVISION 8**  
**in Part C of the *Food and Drug Regulations***



**NDS-D: NEW DRUG SUBMISSIONS-DISINFECTANT DRUGS****SUBMISSIONS RECEIVED****NDS-D: Received by Fee Category**

NDS-D - NEW DRUG SUBMISSION-DISINFECTANTS	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
ADMINISTRATIVE	0	0	0	0	1
DISINFECTANTS	1	1	0	0	0
<i>Total</i>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>

**WORKLOAD****NDS-D: Review Workload/Backlog at End of Quarter**

NNHPD NDS-D REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Disinfectants	3	1	2	1	1
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>3</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>1</b>
Non Backlog	3	1	2	1	1
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

**NDS-D: Screening Workload/Backlog at End of Quarter**

NNHPD NDS-D SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Disinfectants	1	2	0	0	0
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>
Non Backlog	1	2	0	0	0
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

**NDS-D: Administrative-Screening Workload/Backlog at End of Quarter**

NNHPD NDS-D ADMIN SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
Administrative	0	0	0	0	1
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>
Non Backlog	0	0	0	0	1
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## PERFORMANCE

### NDS-D: Review Performance

REVIEW Quarter	OVER TARGET	UNDER: 0-7 DAYS	UNDER: 1 WEEK +	Percent within Target	Total
Jul-Sep 2017	0	1	0	100%	1
Oct-Dec 2017	0	2	0	100%	2
Jan-Mar 2018	0	0	0	-	0
Apr-Jun 2018	0	1	0	100%	1
Jul-Sep 2018	0	0	0	-	0

### NDS-D: Screening Performance

SCREENING Quarter	OVER TARGET	UNDER: 0-7 DAYS	UNDER: 1 WEEK +	Percent with Target	Total
Jul-Sep 2017	0	0	0	-	0
Oct-Dec 2017	0	1	0	100%	1
Jan-Mar 2018	0	5	0	100%	5
Apr-Jun 2018	0	0	0	-	0
Jul-Sep 2018	0	0	0	-	0

### NDS-D: Administrative-Screening Performance

ADMIN SCREENING Quarter	OVER TARGET	UNDER: 0-7 DAYS	UNDER: 1 WEEK +	Percent with Target	Total
Jul-Sep 2017	0	0	0	-	0
Oct-Dec 2017	0	0	0	-	0
Jan-Mar 2018	0	0	0	-	0
Apr-Jun 2018	0	0	0	-	0
Jul-Sep 2018	0	1	0	100%	1

## DECISION DOCUMENTS

### NDS-D: Decision Documents by Fee Category

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
ADMINISTRATIVE	CANCELLATION LETTER	0	0	0	0	0
	SCREENING DEFICIENCY NOTICE	0	0	0	0	1
DISINFECTANTS	NOTICE OF NON-COMPLIANCE	0	0	0	0	0
	NOTICE OF DEFICIENCY	1	1	1	0	0
	NOD WITHDRAWAL LETTER	0	0	1	0	0
	NOTICE OF COMPLIANCE*	0	1	0	1	0
	CANCELLATION LETTER	0	0	0	0	0
	REJECTION LETTER (SCR)	0	0	1	0	0
	SCREENING DEFICIENCY NOTICE	0	1	1	0	0

\*Approvals are the NOCs Issued or Issuable at the conclusion of review (not NOCs issued at the end of a switch or patent hold).

**NC: NOTIFIABLE CHANGES****SUBMISSIONS RECEIVED****NC – Disinfectant Drugs: Received by Fee Category**

NOTIFIABLE CHANGE - NEW DRUG (NC)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
SAFETY 90	0	1	0	0	0

**WORKLOAD****NC – Disinfectant Drugs: Review Workload/Backlog at End of Quarter**

NNHPD NC-DIS REVIEW WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>SAFETY 90</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Non Backlog</b>	0	1	0	0	0
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

**NC – Disinfectant Drugs: Screening Workload/Backlog at End of Quarter**

NNHPD NC-DIS SCREENING WORKLOAD BY FEE CATEGORY AND END OF QUARTER					
	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30
<b>SAFETY 90</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<i>Backlog</i>	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Non Backlog</b>	0	0	0	0	0
<b>BACKLOG</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>% in Backlog</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>

## PERFORMANCE

### NC – Disinfectant Drugs: Review Performance

REVIEW Quarter	OVER TARGET	UNDER: 0-7 DAYS	UNDER: 1 WEEK +	Percent within Target	Total
Jul-Sep 2017	0	0	0	-	0
Oct-Dec 2017	0	0	0	-	0
Jan-Mar 2018	0	0	1	100%	1
Apr-Jun 2018	0	0	0	-	0
Jul-Sep 2018	0	0	0	-	0

### NC – Disinfectant Drugs: Screening Performance

SCREENING Quarter	OVER TARGET	UNDER: 0-7 DAYS	UNDER: 1 WEEK +	Percent within Target	Total
Jul-Sep 2017	0	0	0	-	0
Oct-Dec 2017	0	1	0	100%	1
Jan-Mar 2018	0	0	0	-	0
Apr-Jun 2018	0	0	0	-	0
Jul-Sep 2018	0	0	0	-	0

## DECISION DOCUMENTS

### NC – Disinfectant Drugs: Decision Documents

User Fee Category	Decision	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
SAFETY 90	NO OBJECTION LETTER	0	0	1	0	0
	CANCELLATION LETTER	0	0	0	0	0

**MPNDS: PRE-NDS MEETING****MPNDS – Disinfectant Drugs: Received by Fee Category**

PRE - NDS MEETING (MPNDS)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
CLINICAL OR NON-CLINICAL DATA AND CHEMISTRY - MANUFACTURING	0	0	0	0	0

**MPSNDS: PRE-SNDS MEETING****MPSNDS – Disinfectant Drugs: Received by Fee Category**

PRE - SNDS MEETING (MPSNDS)	Jul-Sep 2017	Oct-Dec 2017	Jan-Mar 2018	Apr-Jun 2018	Jul-Sep 2018
Submission Type - User Fee Category					
CLINICAL OR NON-CLINICAL DATA	0	0	0	1	0